|Articles|August 15, 2002

Study promising: Joint venture to target dry AMD treatment

St. Louis, MO-TLC Vision Corp. has made an equity investment in Vascular Sciences Corp. to establish OccuLogix, a 50/50 joint venture to commercialize Vascular Sciences' Rheopheresis blood filtration process for treating age-related macular degeneration (AMD).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Latest CME